Pharmaceutical Firms

Biocon raises ₹4,150 crore via QIP issue on strong investor demand

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process. The initiative saw issuance of 1,12,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per share, the Bengaluru-based firm said in a regulatory filing. The QIP, which opened on January 12 and closed on January 14, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in the company's growth prospects, it added. The proceeds from the QIP will be primarily utilised to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Ltd, including repayment of debt availed in this regard, Biocon said. The company recently announced its board has approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon

Indian pharma companies see sharp drop in adverse USFDA findings in 2025

OAI cases nearly halve in 2025, overall inspection volumes also fell 25%

Antique prefers domestic-focused pharma firms; resumes coverage on 4 stocks

Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating

Synergy gains from stake purchase positive for pharma major Biocon

Brokerages say Biocon's move to fully acquire Biocon Biologics simplifies structure and unlocks value, but near-term stock pressure likely due to dilution and fundraising

Biocon to make Biocon Biologics a wholly owned subsidiary in $5.5 bn deal

Biocon Biologics Chief Executive Shreehas Tambe will become CEO and managing director of the combined entity post-integration

Can Ozempic trigger depression or suicidal thoughts? Australia weighs in

Australia has issued a safety alert on GLP-1 drugs after reviewing reports of depression and suicidal thoughts; while there is no proven causal link, regulators want users to stay alert

Sun Pharma unit to invest ₹3,000 cr for new plant in Madhya Pradesh

A unit of Sun Pharmaceutical Industries plans to invest Rs 3,000 crore on a new manufacturing plant in Madhya Pradesh, according to a regulatory filing. The board of Sun Pharma Laboratories Ltd, a wholly-owned subsidiary of the company, has approved the proposal for setting up a greenfield formulations manufacturing facility in the state, the Mumbai-based drug major said in a filing on Tuesday. Shares of Sun Pharma on Wednesday ended 0.43 per cent higher at Rs 1,805.70 apiece on BSE.

Emcure Q2 PAT up 25%, domestic and international biz drive 13% revenue rise

The company's revenue from operations rose to Rs 2,269.8 crore, a 13.4 per cent increase from Rs 2,001.9 crore in Q2FY25

Pharma units likely to face action for Schedule M violations: Experts

The one-year grace period for MSME drug manufacturers to comply with revised Schedule M norms has ended, with the CDSCO instructing state regulators to initiate inspections & action against violators

Pfizer signs deal with Metsea after bidding war with Novo Nordisk

The deal comes as Pfizer is attempting to develop its own stake in that market, several months after ending development of a potential pill treatment for obesity

Mounjaro India's bestselling drug in October with ₹100 crore sales

Weight-loss drug rakes in ₹333 cr in cumulative sales since launch in March this year, leaving rival Wegovy behind

Zydus gets USFDA's orphan drug designation for beta-thalassemia product

Zydus Lifesciences on Thursday said the US health regulator has granted Orphan Drug Designation (ODD) to Desidustat, a novel product for the treatment of beta-thalassemia. The US Food and Drug Administration (USFDA) grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 2 lakh people in the US. "This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop Desidustat to address beta-thalassemia," Zydus Lifesciences MD Sharvil Patel said in a regulatory filing. Beta thalassaemia patients have low levels of haemoglobin, which results in a lack of oxygen in many parts of the body, leading to weakness, fatigue and more serious complications. Treatment for people with beta thalassaemia often requires lifelong regimens of chronic blood transfusions for survival and treatment for iron overload due to the transfusions. Desidustat is a hypoxia inducible factor (HIF)-prolyl hydroxylase inhibitor (PHI) an

Alembic Pharma Q2 profit rises 21% on robust US generics and API growth

Alembic Pharma's consolidated profit rose 21% to Rs 185 crore in Q2 FY26, led by strong performance in US generics, APIs, and international markets, with six new ANDA approvals

Cough syrup tragedy: SIT arrests wife of accused Dr Praveen Soni

The SIT investigating the cough syrup tragedy that claimed the lives of 24 children in Madhya Pradesh has arrested the wife of accused Dr Praveen Soni, an official said on Tuesday. Chhindwara-based Dr Soni, who allegedly prescribed the contaminated cough syrup 'Coldrif' to most of the ailing kids, was arrested last month for alleged negligence in connection with the child deaths due to kidney failure. His wife Jyoti Soni, another accused in the case, was arrested from her residence in Parasia town of Chhindwara district on Monday night, Sub Divisional Office of Police and Special Investigation Team (SIT) in-charge Jitendra Jaat said. She is the proprietor of a medical shop from where the cough syrup was sold to several victims, the official said. So far, seven persons have been arrested in connection with the cough syrup tragedy, he added. Following the child deaths, the Tamil Nadu government revoked the licence of the cough syrup manufacturing company, Sresan Pharma. Those arres

Pfizer sues to stop rival bid for Metsera by Denmark's Novo Nordisk

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark's Novo Nordisk, over a bid for Metsera that Novo announced Thursday. Novo said it planned to buy Metsera in a deal that could be worth up to $9 billion, and Metsera said the offer appeared to be superior to Pfizer's bid, which was announced in September. Metsera Inc has no products on the market, but it is developing potential oral and injectable treatments. That includes some potential treatments that could target lucrative fields for obesity and diabetes. Novo already has the treatments Wegovy and Ozempic on the market in those respective categories. Pfizer said the offer from Novo cannot be considered superior to its bid because it carries significant regulatory risk that makes it unlikely to be completed. Pfizer, which ended development of a potential pill to

Achin Gupta to succeed Umang Vohra as Cipla MD & GCEO from April 2026

Umang Vohra joined Cipla in 2015 as global chief financial and strategy officer and thereafter served as the company's MD & GCEO since 2016

India's pharma, healthcare deals surge 166% to $3.5 bn in Q3: Report

Grant Thornton Bharat says India's pharma and healthcare sectors saw renewed investor confidence, driven by consolidation across pharma, biotech, and hospital segments

Laurus Labs shares drop 3% despite analysts' bullish outlook; details here

Laurus Labs reported a strong Q2 FY26 performance, with consolidated net profit soaring multifold to ₹194.97 crore, compared with ₹19.78 crore in Q2 FY25

Govt to tighten rules for sale of oral formulations containing alcohol

Health Ministry also mandates QR codes on vaccines and anti-cancer meds, eases sales licence norms for liquid antiseptics

Biocon Biologics expands Civica tie-up to launch pvt-label insulin in US

The move aims to increase the availability of affordable insulin for the country's 38.4 million diabetes patient